Company Overview - Danaher Corporation (DHR) is a Washington, D.C.-based company that designs, manufactures, and markets professional, medical, research, and industrial products and services, with a market cap of $162.7 billion [1]. Earnings Expectations - Analysts anticipate that DHR will report a profit of $2.14 per share on a diluted basis for the fiscal fourth quarter of 2025, which is unchanged from the same quarter last year [2]. - For the full fiscal year, analysts expect DHR to report an EPS of $7.71, reflecting a 3.1% increase from $7.48 in fiscal 2024, and an expected rise to $8.38 in fiscal 2026, representing an 8.7% year-over-year growth [3]. Stock Performance - DHR stock has underperformed compared to the S&P 500 Index, which gained 16.2% over the past 52 weeks, with DHR shares down slightly during this period. It also underperformed the Health Care Select Sector SPDR Fund, which returned 13.7% in the same timeframe [4]. Market Challenges - The underperformance of Danaher is attributed to a cautious outlook amid uncertainties, including challenges from China's policy and restrained spending in life sciences. Management anticipates a modest recovery in bioprocessing and diagnostics while working to mitigate the impacts of China's volume-based procurement and localize manufacturing [5]. Recent Financial Results - On October 21, 2025, DHR shares rose by 5.9% following the release of Q3 results, where the adjusted EPS of $1.89 exceeded Wall Street expectations of $1.71. The company's revenue reached $6.1 billion, surpassing forecasts of $6 billion. DHR expects full-year adjusted EPS to be in the range of $7.70 to $7.80 [6]. Analyst Ratings - The consensus opinion among analysts on DHR stock is bullish, with a "Strong Buy" rating overall. Out of 23 analysts, 18 recommend a "Strong Buy," one suggests a "Moderate Buy," and four give a "Hold." The average analyst price target for DHR is $258.24, indicating a potential upside of 9.2% from current levels [7].

Core Viewpoint - Danaher Inc. has shown modest stock performance with a slight increase in both the past month and year, leading to mixed sentiments among shareholders regarding its valuation [1]. Stock Performance - The current trading price of Danaher Inc. is $231.47, reflecting a 0.28% increase [1]. - Over the past month, the stock has increased by 2.07%, while in the past year, it has risen by 0.16% [1]. P/E Ratio Analysis - The P/E ratio is a critical metric for long-term shareholders to evaluate Danaher's market performance against historical earnings and industry standards [5]. - Danaher has a lower P/E ratio compared to the aggregate P/E of 562.66 for the Life Sciences Tools & Services industry, which may suggest either underperformance or undervaluation [6]. - A low P/E ratio can indicate potential undervaluation but may also reflect weak growth prospects or financial instability [10]. Investment Considerations - The P/E ratio should be used cautiously as it is just one of many metrics for assessing a company's financial health [9][10]. - Investors are encouraged to consider a comprehensive approach that includes other financial ratios, industry trends, and qualitative factors for informed decision-making [10].

来源：美通社 上海2025年12月25日 /美通社/ -- 12月12日，贝克曼库尔特生命科学在中国的本土化布局迎来又一重要进 展。首批由苏州工厂本地量产的Optima XPN-100超速离心机正式下线，标志着公司在中国已具备超速 离心机的完整本土化生产与质量验证能力。 这一节点不仅是生产环节的落地，更意味着贝克曼库尔特生命科学在中国正式形成支撑高端离心设备量 产的工程化与质量管理体系，为未来更广范围的高端仪器本地化奠定了可持续的能力基础。 以稳健方式共同见证量产里程碑 自1949年推出首台商用制备型超速离心机以来，贝克曼库尔特始终以开创者姿态驱动离心技术发展。历 经七十余载创新传承，Optima XPN-100作为贝克曼库尔特生命科学的旗舰款超速离心机，不仅是技术 参数的集大成者，更是十万转超速时代的行业图腾——100,000 rpm极限转速、802,000 x g强大离心力、 智能温控、动态惯量检测等革命性创新，为核酸、蛋白质、病毒颗粒、外泌体等样本提供高效、高纯度 的分离保障。从开创历史到定义未来，Optima XPN-100承载着贝克曼库尔特生命科学的创新基因，持 续为全球科学家提供稳定可靠的离心解决 ...

Danaher Corporation (NYSE:DHR) is one of the 14 Best Large Cap Stocks to Invest In Now. On December 9, Goldman Sachs started covering Danaher Corporation (NYSE:DHR), giving the stock a Buy rating and setting the price target at $265. The research firm pointed to the company’s strong $6 billion bioprocessing franchise. Despite a currently muted equipment market, this part of Danaher Corporation’s (NYSE:DHR) business is growing at a high single-digit rate. Goldman Sachs expects overhangs hurting equipment d ...

Key Takeaways Biotechnology segment at DHR posted 6.5% core revenue growth in Q3 2025 on sustained bioprocessing momentum.Strong consumables and mAbs demand drove bioprocessing orders higher for a ninth quarter at Danaher.Despite equipment demand headwinds, Danaher expects Biotechnology core revenues to rise about 5% in Q4 2025.Danaher Corporation (DHR) has been benefiting from strength in its Biotechnology segment. In the third quarter of 2025, the segment’s core revenues increased 6.5% on a year-over-year ...

Core Viewpoint - Multiple scientific instrument manufacturers are announcing price adjustments in response to rising costs of raw materials, labor, and supply chain pressures, which are impacting production and operations [4][6][20]. Group 1: Thermo Fisher - Thermo Fisher has stated that due to macroeconomic factors, the costs of raw materials and intermediate processes for chromatography consumables are increasing, leading to production and operational pressures. As a result, they will adjust their product catalog prices starting January 1, 2026 [4][6]. Group 2: Danaher - Abcam - Danaher has completed a review of its entire product line and will implement necessary price adjustments due to rising costs in key areas. The new prices will take effect on January 1, 2026, with variations depending on the product line [8][11]. Group 3: Phenomenex - Phenomenex has decided to adjust market pricing for its products in China due to challenges posed by the global economic environment and supply chain issues. The price adjustments will vary by product line and will be effective from December 22, 2025 [15][16]. Group 4: PerkinElmer - PerkinElmer has indicated that due to multiple factors, including significant increases in core procurement costs due to tariffs, they will adjust prices for consumables starting January 1, 2026. The adjustments will vary by product [20][22]. Group 5: Jena - Jena has announced that due to macroeconomic influences leading to rising production costs, they will adjust prices for both main instruments and consumables starting January 1, 2026 [25]. Group 6: ATAGO - ATAGO has communicated that due to ongoing global economic instability and rapid increases in industry costs, they will raise prices on certain products effective December 1, 2025. Specific details can be obtained from regional sales representatives [29][32].

WASHINGTON, Dec. 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2025 on Wednesday, January 28, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subhe ...

来源：管理智慧 导读 本文剖析了丹纳赫（Danaher）如何凭借其核心方法论——DIVE问题解决流程，成为全球并购整合与持续运营的标杆。丹纳赫给我们最深刻的启示是：在 充满不确定性的时代，企业最核心的竞争力之一，是系统化、可持续解决问题的能力。 作者 | 韩勇 原创出品 | 管理智慧 丹纳赫凭什么成为全球标杆？ 企业里的问题似乎永远解决不完。为什么？ 其实，大多数企业不是不想解决问题，而是不知道怎么真正的解决问题。 我们以为在解决问题，实际上只是在处理症状。 说到系统化解决问题，不得不提一家公司——丹纳赫。 从1984年上市至今，丹纳赫股价涨了超600倍，长期投资回报远超巴菲特的伯克希尔。更重要的是，它通过持续并购整合了几十家企业，却能让每一家都 脱胎换骨，业绩大幅提升。 秘诀是什么？就是丹纳赫业务系统(DBS)，而丹纳赫问题解决流程就是这个系统的核心方法论之一。 这套方法论借鉴了丰田的问题解决流程，但又做了系统化的改进。这是一个简洁的四步框架，英文缩写是DIVE： Define（定义问题）：清楚地陈述问题是什么； Investigate（调查分析）：找出问题的根本原因； Verify（验证对策）：验证并实施 ...

Group 1: Procter & Gamble (PG) - Procter & Gamble is highlighted as a favorite tech stock by Cramer, who emphasizes its significant investment in innovation, spending over $2 billion annually on new product development [2] - The company, known for brands like Pampers and Gillette, has seen a nearly 13% decline year-to-date, which Cramer attributes to a de-risking rather than a fundamental issue [2] - Cramer notes that Procter & Gamble has successfully utilized artificial intelligence to enhance its supply chain, leading to substantial cost savings and faster product market introduction [4] Group 2: Danaher (DHR) - Danaher is identified as one of the "out-of-favor stocks to buy," with Cramer suggesting it is poised for recovery after a period of negative performance [4][5] - The company, which provides tools and technologies to the healthcare sector, has experienced a recovery over the past six months, gaining more than 12% [5] - Wells Fargo has raised its price target for Danaher from $230 to $240, anticipating increased organic growth in the life sciences tools industry next year [5]

Shares of Danaher Corporation ( DHR ) quickly reached the target price of $210 after the release of a strong report for the third quarter. I am not changing my view of the companyHi there! I’m Narek, and I’ve been in the investment world for over six years. I started out as an equity analyst at European banks, digging into reports and learning how to spot value in the markets. I’ve worked across sectors — from telecom to industry — and found that behind every financial statement is a real story. I studied i ...